Sehin Birhanu

Sehin Birhanu

Auto-generated profile, based on publicly available information

Sehin Birhanu

Division of Global HIV & TB, CGH, CDC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
AHAndreas D Haas
Andreas D Haas
ERElizabeth Radin
Elizabeth Radin
SBSehin Birhanu
Sehin Birhanu
ALAndrea J Low
Andrea J Low
SSSuzue Saito
Suzue Saito
JJJessica E Justman
Jessica E Justman
Introduction: Late diagnosis of HIV (LD) increases the risk of morbidity, mortality, and HIV transmission. We used nationally representative data from population-based HIV impact assessment (PHIA) surveys in Malawi, Zambia, and Zimbabwe (2015–2016) to characterize adults at risk of LD and to examine associations between LD and presumed HIV transmission to cohabiting sexual partners. Methods: We estimated the prevalence of LD, defined as CD4 count <350 cells/μL, among adults newly diagnosed with HIV during the surveys and odds ratios for associated factors. We linked newly diagnosed adults (index cases) to their household sexual partners and calculated adjusted odds ratios for associations between LD of the index case, viral load of the index case, and duration of HIV exposure in the relationship, and the HIV status of the household sexual partner. Results: Of 1,804 adults who were newly diagnosed with HIV in the surveys, 49% (882) were diagnosed late. LD was associated with male sex, older age, and almost five times the odds of having an HIV-positive household sexual partner (adjusted odds ratio [aOR], 4.65 [95% confidence interval: 2.56–8.45]). Longer duration of HIV exposure in a relationship and higher viral load of the index case were both independently associated with higher odds of having HIV-positive household sexual partners. Individuals with HIV exposure of more than 5 years had more than three times (aOR 3.42 [95% CI: 1.63–7.18]) higher odds of being HIV positive than those with less than 2 years HIV exposure. The odds of being HIV positive were increased in individuals who were in a relationship with an index case with a viral load of 400–3499 copies/mL (aOR 4.06 [95% CI 0.45–36.46]), 3,500–9,999 copies/mL (aOR 11.32 [95% CI: 4.08–31.39]), 10,000–49,999 copies/mL (aOR 17.07 [95% CI: 9.18–31.72]), and ≥50,000 copies/mL (aOR 28.41 [95% CI: 12.18–66.28]) compared to individuals who were in a relationship with an index case with a viral load of <400 copies/mL. Conclusions: LD remains a challenge in Southern Africa and is strongly associated with presumed HIV transmission to household sexual partners. Our study underscores the need for earlier HIV diagnosis, particularly among men and older adults, and the importance of index testing.

29 July 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
HPHetal K Patel
Hetal K Patel
SISunday Ikpe
Sunday Ikpe
MBMegan Bronson
Megan Bronson
SBSehin Birhanu
Sehin Birhanu
AAAlash'le Abimiku
Alash'le Abimiku
BPBharat S Parekh
Bharat S Parekh
Background: The Nigeria AIDS Indicator and Impact Survey (NAIIS), a cross-sectional household survey, was conducted in 2018 with primary objectives to estimate HIV prevalence, HIV-1 incidence, and status of UNAIDS 90-90-90 cascade. We conducted retrospective analysis of the performance of HIV rapid tests and the national HIV testing algorithm used in Nigeria. Methods: The national algorithm included Determine HIV-1/2 as test 1 (T1), Unigold HIV-1/2 as test 2 (T2), and StatPak HIV-1/2 as the tie-breaker test (T3). Individuals reactive with T1 and either T2 or T3 were considered HIV-positive. HIV-positive specimens from the algorithm were further confirmed for the survey using supplemental test Geenius HIV-1/2. If Geenius did not confirm HIV-positive status, HIV-1 Western blot was performed. We calculated the concordance between tests and positive predictive value (PPV) of the algorithm on unweighted data. Results: Of 204,930 participants (ages ≥18 months) 5,103 (2.5%) were reactive on T1. Serial testing of T1 reactive specimens with T2 or if needed by tiebreaker T3 identified 2958 (1.44%) persons as HIV-positive. Supplemental testing confirmed 2,800 (95%) as HIV-positive (HIV-1 = 2,767 [98.8%]; HIV-2 = 5 [0.2%]; dual infections = 22 [0.8%]). Concordance between T1 and T2 was 56.6% while PPV of the national algorithm was 94.5%. Conclusions: Our results show high discordant rates and poor PPV of the national algorithm with a false-positive rate of about 5.5% in the NAIIS survey. Considering our findings have major implications for HIV diagnosis in routine HIV testing services, additional evaluation of testing algorithm is warranted in Nigeria.

15 June 2023 in Microbiology Spectrum
Verified
Journal Article
Closed access
SBSehin Birhanu
Sehin Birhanu
FWFrieda S. Winterhalter
Frieda S. Winterhalter
PSPaul Stupp
Paul Stupp
MCMelissa Cates
Melissa Cates
ERErin Rottinghaus
Erin Rottinghaus
HPHetal K Patel
Hetal K Patel
The manuscript describes CD4 levels among HIV-positive individuals and baseline CD4 levels among HIV-negative individuals from 11 sub-Saharan countries, thereby highlighting the importance of CD4 markers in the context of the HIV epidemic. Despite increased ARV access in each country, advanced HIV disease (CD4 < 200 cells/mm 3 ) persists among approximately 11% of HIV-positive individuals.

17 December 2025 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
HPHetal K Patel
Hetal K Patel
YDYen T. Duong
Yen T. Duong
SBSehin Birhanu
Sehin Birhanu
MMMelissa Metz
Melissa Metz
JGJared Garfinkel
Jared Garfinkel
BPBharat S Parekh
Bharat S Parekh
Population-based HIV Impact Assessment surveys were conducted in 14 countries to measure HIV prevalence, incidence, and viral load suppression in children aged 0–14 years and adults aged ≥15 years. We examined the performance of rapid HIV testing algorithms in multiple countries. Survey participants received an HIV diagnosis based on two serial tests in Cameroon, Côte d’Ivoire, Eswatini, Haiti, Kenya, Lesotho, Malawi, Mozambique, Tanzania, and Zambia. Whereas in Ethiopia, Kenya, Namibia, Uganda, and Zimbabwe, diagnosis was based on a tie-breaker algorithm. Testers received intensive training on specimen collection, testing, and results reporting. HIV-positive and indeterminate results were confirmed by Geenius HIV-1/2 test (Bio-Rad). Pooled test 1 and 2 positive concordance, test 2 and 3 negative concordance, and the positive predictive value (PPV) of the algorithm were calculated. A total of 312,069 participants aged ≥18 months (except for Eswatini, Mozambique, and Uganda, where only adults aged 15+ years were included) were tested by either the two-test ( n = 243,311) or tie-breaker ( n = 98,757) algorithm for diagnosis. The combined test 1 and 2 positive concordance and PPV were 93.8% and 99.4%, respectively, for countries with a two-test algorithm. Similarly, test 1 and 2 positive concordance, test 2 and 3 negative concordance, and PPV were 87.5%, 84.4%, and 98.8%, respectively, for the tie-breaker algorithm. The PPV ranged from 94.2% to 99.9%, with higher PPV in high burden countries. The HIV testing algorithms performed with high accuracy, with PPV reaching 99% or higher. Adoption of continuous quality improvement is essential to ensure accuracy of HIV diagnosis in service delivery settings. IMPORTANCE: HIV diagnostic testing in most African countries follows national algorithms that typically use two tests, with or without a tie-breaker. We assessed the accuracy of these algorithms using data from population-based surveys in 14 sub-Saharan African countries, where all HIV-positive results were further confirmed with the Geenius HIV-1/2 supplemental assay. Our findings show that inter-test concordance and positive predictive values (PPVs) varied by HIV prevalence, with higher PPVs observed in higher-prevalence settings. Overall, the PPV of HIV diagnosis was close to 99%, indicating that two-test algorithms can provide highly accurate results when testing is performed with strict adherence to quality standards and tester competency. These results underscore the importance of quality assurance (QA) and suggest that countries with lower HIV prevalence may benefit from adopting a three-test algorithm. However, such changes should be accompanied by careful attention to logistics, procurement, training, record keeping, and other QA measures.

11 December 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
CWChristine A West
Christine A West
EMElisabeth Mungai
Elisabeth Mungai
SBSehin Birhanu
Sehin Birhanu
RLRebecca Laws
Rebecca Laws
EAElfriede Agyemang
Elfriede Agyemang
AVAndrew Charles Voetsch
Andrew Charles Voetsch
Background: Limited population data exist assessing trends in advanced HIV disease (AHD) in the test-and-treat era. We examined changes in AHD prevalence from 2015 to 2017 (round 1) and 2019 to 2023 (round 2) in 7 African countries. Methods: We pooled data from 2 rounds of the Population-Based HIV Impact Assessment (PHIA) surveys from 7 countries among persons with HIV (PWH) aged 15 to 59 years. AHD was defined as having an HIV-positive result and CD4 <200 cells/mm3. Awareness of HIV diagnosis and treatment status were based on self-report and detection of antiretrovirals. Weighted estimates between survey rounds were compared through complex survey methods. Results: Across all countries, 13.2% and 6.8% of PWH met criteria for AHD during rounds 1 and 2, respectively. AHD prevalence among those aware of their HIV status and not on antiretroviral therapy (ART) increased by 31.7% (20.8% to 27.4%) but decreased by 17.7% (17.5% to 14.4%) among those unaware and not on ART and by 53.3% (10.5% to 4.9%) among those aware and on ART. The adjusted odds ratio for AHD comparing rounds 1 and 2 among those aware and on ART was 0.46 (95% CI, 0.39–0.53). Those who were aware and on ART accounted for the majority of PWH with AHD in both rounds (51.6%, round 1; 58.8%, round 2). Conclusions: These findings indicate substantial reductions in AHD prevalence among those on ART between 2015–2017 and 2019–2023. Continued efforts are warranted to ensure timely diagnoses and treatment adherence and reduce barriers to care reengagement, which represent an increasingly important driver of AHD.